<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305563</url>
  </required_header>
  <id_info>
    <org_study_id>CA212-016</org_study_id>
    <nct_id>NCT02305563</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of ulocuplumab in
      combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid
      Leukemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing a ulocuplumab-related dose limiting toxicity (DLT) during the DLT evaluation period based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Grade 3 or higher Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) leading to discontinuation</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) leading to death</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Laboratory Abnormalities</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response based on the Rate of Complete Remission (CR/CRi)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort) Complete Remission (CR), Complete Remission with incomplete blood count recovery (CRi), Rate of Complete Remission (CR/CRi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed best overall response(BOR) using AML response criteria</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) leading to discontinuation</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) leading to death</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Laboratory Abnormalities</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-drug antibody(ADA) positive for ulocuplumab</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed ulocuplumab serum concentration (Tmax)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the ulocuplumab concentration-time curve from time zero to the last quantifiable concentration (AUC(0-T))</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the ulocuplumab concentration-time curve in one dosing interval (AUC{TAU})</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the ulocuplumab concentration-time curve from time zero to infinity (AUC(INF))</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half life (T-HALF)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of ulocuplumab</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in electrocardiogram(ECG) intervals</measure>
    <time_frame>Baseline up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Remission (OR) as determined by investigator assessment using AML response criteria</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete Remission (CR/CRi) as determined by investigator assessment using AML response criteria</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Complete Remission (CR), Complete Remission with incomplete blood count recovery (CRi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall survival: Defined as the time between the date of randomization and the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Ulocuplumab + low dose Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulocuplumab Dose A + low dose Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulocuplumab Dose B + low dose Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose Cytarabine only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low Dose Cytarabine only Phase 2 (expansion cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-936564</intervention_name>
    <arm_group_label>Ulocuplumab + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose A + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose B + low dose Cytarabine</arm_group_label>
    <arm_group_label>low dose Cytarabine only</arm_group_label>
    <other_name>Ulocuplumab</other_name>
    <other_name>MDX-1338</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Ulocuplumab + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose A + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose B + low dose Cytarabine</arm_group_label>
    <arm_group_label>low dose Cytarabine only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Newly Diagnosed Acute Myeloid Leukemia (AML)

          -  Considered inappropriate for intensive remission induction therapy by an investigator

          -  Not eligible for stem cell transplantation

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Current Myelodysplastic syndrome only subjects

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>1138677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>November 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
